Aquestive Therapeutics, Inc. AQST Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.45M+11.0% | $13.02M+1.6% | $12.81M+28.0% | $10M+14.7% | $8.72M-26.5% | ||
| $3.47M-40.6% | $5.84M+29.5% | $4.51M-1.2% | $4.56M+24.9% | $3.65M-19.2% | ||
| $10.98M+52.9% | $7.18M-13.5% | $8.3M+52.5% | $5.44M+7.4% | $5.07M-31.0% | ||
| 76%+20.8pp | 55.2%-9.7pp | 64.8%+10.4pp | 54.4%-3.7pp | 58.1%-3.8pp | ||
| $4.2M+31.5% | $3.2M-29.4% | $4.53M+10.4% | $4.11M-23.4% | $5.36M+9.0% | ||
| $10.98M-66.6% | $32.82M+115% | $15.25M+20.0% | $12.71M-33.4% | $19.07M+19.1% | ||
| $18.65M-55.4% | $41.85M+72.3% | $24.29M+13.6% | $21.37M-23.9% | $28.09M+10.4% | ||
| -$4.2M+85.4% | -$28.84M-151% | -$11.48M-1.0% | -$11.37M+41.3% | -$19.37M-42.6% | ||
| -29.1%+192pp | -221.6%-132pp | -89.6%+24.0pp | -113.6%+108pp | -222.1%-108pp | ||
| $2.9M+4.5% | $2.78M0.0% | $2.78M-0.1% | $2.78M0.0% | $2.78M+0.1% | ||
| -$8.06M+74.7% | -$31.86M-106% | -$15.45M-14.0% | -$13.55M+40.9% | -$22.93M-34.3% | ||
| -$8.06M+74.7% | -$31.86M-106% | -$15.45M-14.0% | -$13.55M+40.9% | -$22.93M-34.4% | ||
| -55.8%+189pp | -244.8%-124pp | -120.6%+14.8pp | -135.4%+128pp | -263%-119pp | ||
| -$0.07+74.1% | -$0.27-92.9% | -$0.140.0% | -$0.14+41.7% | -$0.24-26.3% | ||
| -$4.09M+85.8% | -$28.71M-153% | -$11.34M-1.0% | -$11.23M+41.6% | -$19.23M-43.1% | ||
| -28.3%+192pp | -220.6%-132pp | -88.5%+23.7pp | -112.2%+108pp | -220.5%-107pp | ||
| -$4.2M+85.4% | -$28.84M-151% | -$11.48M-1.0% | -$11.37M+41.3% | -$19.37M-42.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aquestive Therapeutics, Inc.'s revenue?
- Aquestive Therapeutics, Inc. (AQST) generated $50.3M in revenue over the trailing twelve months, down 7.3% year over year.
- Is Aquestive Therapeutics, Inc. profitable?
- Aquestive Therapeutics, Inc. is not currently profitable: it reported a net loss of $68.9M over the trailing twelve months, a -137.1% net margin.
- What are Aquestive Therapeutics, Inc.'s profit margins?
- Gross margin is 63.5% and operating margin is -111.2%, with a -137.1% net margin.
- What is Aquestive Therapeutics, Inc.'s earnings per share?
- Aquestive Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.62.
- Where does Aquestive Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
